Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Olverembatinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascentage Pharma Releases Olverembatinib Data In SDH-Deficient GIST
    Ascentage Pharma Releases Olverembatinib Data In SDH-Deficient GIST

    13 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-esmo-2024--ascentage-pharma-releases-latest-data-showing-sustained-clinical-efficacy-of-olverembatinib-in-sdh-deficient-gist-during-a-mini-oral-presentation-302248193.html

    PR NEWSWIRE
    13 Sep 2024
    Share Share
    Olverembatinib Approved for Commercialization in Macau China
    Olverembatinib Approved for Commercialization in Macau China

    07 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/olverembatinib-approved-for-commercialization-in-macau-china-302190451.html

    PR NEWSWIRE
    07 Jul 2024
    Share Share
    Ascentage Pharma Received US$100 Million Option Payment from Takeda
    Ascentage Pharma Received US$100 Million Option Payment from Takeda

    03 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascentage-pharma-received-us100-million-option-payment-from-takeda-302189330.html

    PR NEWSWIRE
    03 Jul 2024
    Share Share
    EHA 2024: Olverembatinib Studies Show Encouraging Data In CML And Ph+ ALL
    EHA 2024: Olverembatinib Studies Show Encouraging Data In CML And Ph+ ALL

    18 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-eha-2024--posters-featuring-results-from-three-studies-of-olverembatinib-including-encouraging-data-from-us-study-in-cml-and-ph-all-302175024.html

    PR NEWSWIRE
    18 Jun 2024
    Share Share
    Takeda Signs Option With Ascentage For Olverembatinib License
    Takeda Signs Option With Ascentage For Olverembatinib License

    14 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240614852542/en

    BUSINESSWIRE
    14 Jun 2024
    Share Share
    China NMPA approves Ascentage Pharma’s phase III study of olverembatinib
    China NMPA approves Ascentage Pharma’s phase III study of olverembatinib

    12 Jun 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=169692&sid=2

    PHARMABIZ
    12 Jun 2024
    Share Share